Competition
Competition — Who Can Hurt Molina, Who It Can Beat
Molina sits in a five-name listed peer arena and one regulator-policed bid table. CNC, ELV, UNH, HUM, and CVS each compete with MOH on at least one of three premium pools (Medicaid, Medicare Advantage / D-SNP, ACA Marketplace) — but the way they hurt MOH is not symmetric, and the one that matters most over the next 24 months is not the largest.
MOH Market Cap ($M)
MOH Medicaid Members (k)
CNC Medicaid Members (k)
UNH C&S Members (k)
The bottom line. Molina has a real but narrow operational advantage in Medicaid — a 6.6% G&A ratio that is best-in-class for the segment, a 90% RFP renewal win rate, and the will to walk away from mis-priced books (2017 Marketplace exit, 2026 Marketplace + MAPD retrenchment). It does not have a structural moat. It is the smallest of six listed payors, owns no PBM, no provider clinics, no analytics services arm, and competes head-to-head on every state RFP with rivals 4x–35x its size. The competitor that hurts MOH most over the next 24 months is UnitedHealth's Community & State business — 7.4M Medicaid lives across 32 states, an Optum vertical-integration stack that captures provider margin MOH gives away, and the balance sheet to underprice on any state bid it wants to win. Centene is the mirror; UnitedHealth is the structural threat; Elevance is the silent share-taker; Humana and CVS are sideshows for the Medicaid franchise.
1. The peer set, and why it is exactly these five
Pure-play government-payor insurance lives in one corner (CNC + MOH); diversified integrated payors in another (UNH, CVS, ELV); a Medicare-Advantage specialist sits alone (HUM). Every other listed payor competes for at least one of MOH's three premium pools:
Who was rejected and why. Cigna (CI) — almost no Medicaid book; Evernorth-led commercial mix skews medians. Oscar (OSCR) — Marketplace-only, no Medicaid, growth-stage. Clover / Alignment — pure-play MA start-ups, dominated by Star Ratings execution. HCA / Tenet / UHS — hospital operators on the other side of the value chain (they receive MOH premium dollars). Bright Health / Friday Health — already wound down; MOH actually absorbed Bright's California MAPD book. Adding any of these would dilute the comparison, not enrich it.
2. The peer comparison table the buy-side reads
Data note. All figures USD, sourced from peer-valuation snapshot dated 2026-06-12 (Yahoo Finance market data; FY2025 10-K and Fiscal.ai income statements for operating metrics). CNC P/E is null because LTM net income is a $6.4B loss after the 2025 Marketplace risk-adjustment miss. ROE for CNC is calculated on positive end-period equity but the LTM denominator is loss-making. No private, subsidiary-only, or delisted competitor in this peer set requires N/A handling — every name is publicly listed on NYSE with full disclosure.
MOH and CNC sit on top of each other in the bottom-left quadrant — the lowest revenue-multiple and thinnest operating margin in the group. The market is pricing both as pure-play government-payor risk: cyclical, no vertical-integration premium, no PBM economics, no commercial diversification. UNH's 0.90x is an 8x premium to MOH's 0.11x. The bull case is that part of that gap closes when MCR turns; the bear case is that the discount is structural — MOH's revenue dollar lacks every margin-lever Optum operates.
3. Where Molina actually wins
Each advantage is tied to evidence in MOH's filings, a competitor 10-K, or the staged data.
The G&A read is the single cleanest "MOH wins" data point. Three competing forces pulled UNH/CVS/ELV G&A higher (Optum/Caremark/Carelon services-revenue, retail-pharmacy fixed costs, Blues administrative complexity). MOH's pure-play Medicaid model strips all of that out — but the trade-off is exactly the absent vertical-integration premium that explains the 8x EV/Revenue gap to UNH.
4. Where competitors are better
Each weakness ties to a named peer and is backed by competitor disclosure or the staged financials.
5. The competitive scorecard — head-to-head, dimension by dimension
How MOH stacks up against each peer on the seven dimensions that actually move state RFP outcomes, CMS contract economics, and buy-side multiples. Cells are scored + (MOH advantage), = (roughly even), − (peer advantage), N/A (not contested).
The scorecard reads cleanly: MOH wins on discipline, loses on structure. The +1 row (G&A) is the entire mid-cycle ROE story — MOH compounds on operating leverage that no diversified payor will ever match in pure-play Medicaid. The two solid −1 rows (Medicaid scale, vertical integration) are the entire investment-discount story. The middle rows depend on management execution from here: D-SNP alignment by 2027, Marketplace exit cleanliness, MA D-SNP-only strategy. All three are open bets.
6. The threat assessment — who can move the stock in 24 months
Six threats ranked by 24-month probability and EPS impact. Severity is High (>15% EPS impact or material moat erosion), Medium (5-15%), Low (<5%).
The single threat that matters most. If forced to pick one: UnitedHealth's Community & State bidding into the 2026-2027 California, Texas STAR Kids, and Georgia RFP cycles. A loss on any of those is a 5-10% premium event with 12-18 month earnings tail; UNH has both the balance sheet and the Optum capture-margin to bid below MOH's actuarial floor. The OBBBA + subsidy story is bigger in dollars over a 3-5 year horizon but plays out evenly across the industry; it does not differentially hurt MOH the way an UNH state win would.
7. Moat watchpoints — what to monitor each quarter
Five measurable, public signals that would actually change the competitive call:
Reading the watchlist together. Items 1-2 are about whether MOH's Medicaid operational discipline keeps producing. Item 3 is the single best external read on whether UNH is going to take MOH share. Item 4 is the multiple risk. Item 5 is the upside option. A clean read in 12 months requires positive movement on at least three of the five — that is what would shift the moat call from "operational and shrinking" to "operational and durable."
8. The competitive bottom line, in one paragraph
MOH's competitive position is real but narrow, and the rivals that matter are not equally dangerous. Centene is the closest comp but the catalyst it offers is sentiment, not share — CNC is wounded, not winning. UnitedHealth is the structural threat: 7.4M Medicaid lives, an Optum margin capture MOH cannot match, and the balance sheet to under-price any state RFP it cares about. Elevance is the silent share-taker in 24 overlapping states. Humana and CVS matter at the seams (D-SNP alignment, MA Stars) but not in the core Medicaid franchise. The moat is operational discipline applied to a regulated cycle: lean G&A, RFP execution skill, willingness to walk from mis-priced books. The short watchlist: renewal awards holding, medical-cost-corridor receivable trend, UHC C&S growth in shared states, Centene returning to positive net income, and D-SNP retention. Three of five moving in MOH's favor over 12 months keeps the cyclical re-rate trade intact; otherwise the discount to UNH is structural, not temporary.